Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501425 | 0.93 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1 | |
| SCHEMBL10278636 | 0.90 | HSP90AA1 (0.36) | HSP90AB1HSP90AA1 | |
| SCHEMBL501477 | 0.84 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1 | |
| SCHEMBL501062 | 0.84 | HSP90AA1 (0.39) | HSP90AB1HSP90AA1 | |
| SCHEMBL500726 | 0.84 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1 | |
| SCHEMBL500819 | 0.83 | HSP90AA1 (0.39) | HSP90AB1HSP90AA1 | |
| SCHEMBL501150 | 0.83 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1 | |
| SCHEMBL501431 | 0.83 | GHSR (0.41) | HSP90AB1HSP90AA1 | |
| SCHEMBL501631 | 0.82 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1 | |
| SCHEMBL500947 | 0.82 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.